Bausch + Lomb – Stada Arzneimittel – Xbrane Biopharma – licensing deal for Lucentis biosimilar
Bausch + Lomb announced an exclusive licensing agreement with Stada Arzneimittel and its development partner Xbrane Biopharma to develop and commercialize a... Read More
Xbrane Signs Deal With Helvetic BioPharma for its Lead Ranibizumab Biosimilar, Xlucane
Posted on18 Jan 2016
TagsBiosimilar of Novartis' eye drug Lucentis launched in India, biosimilar version of Lucentis, biotech companies in the Middle East, Lucentis, Ranibizumab, Ranibizumab biosimilar, Xbrane, Xbrane Signs Deal With Helvetic BioPharma for its Lead Ranibizumab Biosimilar, Xlucane
Comments0
Xbrane Biopharma, a commercial phase biopharmaceutical company specialized in High Demand Complex Generics, announced that the company has signed a sales and... Read More